Skip to main content
. 2020 Oct 22;163(7):2025–2035. doi: 10.1007/s00701-020-04589-y

Table 1.

Infiltrative gliomas—patient’s characteristics

Patient No. Age at diagnosis/sex H3K27 status Diagnosis (WHO 2016) Histological featuresa Localization Degree of resection Adjuvant therapy Follow-up time (years) Follow-up status
1 3/F Mutated DMG H3K27mut Astrocytoma II Thalamic l STR CTX/RTXb,c 9.6 DOD
2 15/F Mutated DMG H3K27mut Oligodendroglioma III Thalamic r STR CTX/RTXc 9.2 CR
3 4/F Mutated DMG H3K27mut Astrocytoma II Thalamic r STR CTX/RTXc 4.0 PD
4 10/F Mutated DMG H3K27mut Astrocytoma III Thalamic l Biopsy CTX/RTXe 1.5 DOD
5 9/M Mutated DMG H3K27mut Astrocytoma III Thalamic r STR CTX/RTXe 1.1 DOD
6 5/F Mutated DMG H3K27mut Astrocytoma III Bithalamic Biopsy CTX/RTXc 1.1 DOD
7 13/F Mutated DMG H3K27mut Astrocytoma III Thalamic r Biopsy CTX/RTXc 0.8 DOD
8 5/M Mutated DMG H3K27Mmut Astrocytoma III Bithalamic Biopsy CTX/RTXd 0.6 DOD
9 8/M Mutated DMG H3K27Mmut GBM Thalamic l STR CTX/RTXc 2.0 DOD
10 9/M Mutated DMG H3K27mut GBM Thalamic l STR CTX/RTXc 1.6 DOD
11 8/M Mutated DMG H3K27mut GBM Thalamic l STR CTX/RTXc 1.2 DOD
12 9/F Mutated DMG H3K27mut GBM Thalamic l PR CTX/RTXe 0.9 DOD
13 9/F Mutated DMG H3K27Mmut GBM Thalamic r PR CTX/RTXc 0.5 DOD
14 17/F Mutated DMG H3K27mut GBM Thalamic r PR RTX 0.4 DOD
15 11/M Wild-type H3K27me3-loss GBM GBM Thalamic l PR CTX/RTXc 1.5 PD
16 5/M Wildtype; H3K27me3-loss AA,NOS Astrocytoma III Bithalamic Biopsy CTX/RTXe 0.9 DOD
17 15/F Wildtype AA , IDHwt Astrocytoma III Bithalamic PR CTX/RTXc 7.6 SD
18 11/M Wildtype AA, IDHwt Astrocytoma III Bithalamic Biopsy CTX/RTXc 1.2 DOD
19 17/M Wildtype AA, IDHwt Astrocytoma III Thalamic r STR CTX/RTXf 0.9 DOD
20 4/M Wildtype AA, IDHwt Astrocytoma III Thalamic l Biopsy CTX/RTXc 0.7 DOD
21 7/F Wildtype LGG, NOS Astrocytoma II Thalamic r PR - n/a LTFU
22 9/M Wildtype LGG, NOS Astrocytoma II Bithalamic PR CTXg 20.0 SD
23 5/M n/a Diffuse A, NOS Astrocytoma II Thalamic l Biopsy CTX/RTXd 4.0 DOD
24 15/M n/a AA, , NOS Astrocytoma III Thalamic l PR CTX/RTXd 3.0 DOD
25 18/M n/a Anaplastic oligoastrocytoma, NOS Oligoastrocytoma III, Bithalamic Biopsy CTX/RTXc 2.0 DOD

AA, anaplastic astrocytoma; CTX, chemotherapy; DMG, diffuse midline glioma; DOD, death of disease; GBM, glioblastoma; LGG, low-grade glioma; LTFU, lost to follow-up; NOS, not otherwise specified; STR, subtotal resection; PR, partial resection; RTX, radiotherapy; SD, stable disease; M/F, male/female; r/l right/left

aAs defined by the 2007 4th edition of the WHO classification of tumours of the central nervous system (25). bAt recurrence 9 years after primary diagnosis. cHIT-HGG-2007. dHIT-GBM-C (41). eHIT-GBM-D (42). fHIT 2000 (14). gHIT-LGG-1996 (15)